Preoperative C-Reactive Protein/Albumin Ratio Predicts Prognosis of Patients after Curative Resection for Gastric Cancer

Xuechao Liu, Xiaowei Sun, Jianjun Liu, +4

Translational Oncology

The systemic immune-inflammation index is an independent predictor of survival for metastatic colorectal cancer and its association with the lymphocytic response to the tumor

Qiankun Xie, Ping Chen, Wanming Hu, +10

Journal of Translational Medicine

Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma

Rui-Yan Wu, Pengfei Kong, Liang-Ping Xia, +17

Clinical Cancer Research

Activation of MAT2A-ACSL3 pathway protects cells from ferroptosis in gastric cancer

Mingzhe Ma, Pengfei Kong, Yakai Huang, +6

Free Radical Biology and Medicine

Prognostic value of total number of lymph nodes retrieved differs between left-sided colon cancer and right-sided colon cancer in stage III patients with colon cancer

Lin Yang, Zhenchong Xiong, Qiankun Xie, +6

BMC Cancer

Prognostic value of pretreatment albumin–globulin ratio in predicting long-term mortality in gastric cancer patients who underwent D2 resection

Jianjun Liu, Shangxiang Chen, Qirong Geng, +4

OncoTargets and Therapy

Development and external validation of a prognostic nomogram for gastric cancer using the national cancer registry

Jianjun Liu, Qirong Geng, Zhimin Liu, +8

Oncotarget

External ValidationSurgical OncologyPrognosisGastroenterologyPathology +14

SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA

Ruiyan Wu, Caiqin Wang, Zhiming Li, +16

Journal for ImmunoTherapy of Cancer

Enhanced antitumor efficacy through microwave ablation in combination with immune checkpoints blockade in breast cancer: A pre-clinical study in a murine model

Junhao Zhu, Mengxue Yu, L Chen, +10

Diagnostic and Interventional Imaging

Breast OncologyMedicineImmunologyImmune Checkpoint InhibitorBreast Cancer +8

Gastric cancer, nutritional status, and outcome

Xuechao Liu, Haibo Qiu, Pengfei Kong, +2

OncoTargets and Therapy